Pure Bioscience Stock Today
| PURE Stock | USD 0.05 0.0004 0.80% |
PerformanceWeakest
| Odds Of DistressSmall
|
Pure Bioscience is trading at 0.0496 as of the 29th of January 2026, a 0.8 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0426. Pure Bioscience has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 31st of October 2025 and ending today, the 29th of January 2026. Click here to learn more.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. The company has 111.36 M outstanding shares of which 222.97 K shares are at this time shorted by private and institutional investors with about 2.56 trading days to cover. More on Pure Bioscience
Moving together with Pure OTC Stock
| 0.61 | DSKYF | Daiichi Sankyo Earnings Call Tomorrow | PairCorr |
Moving against Pure OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Pure OTC Stock Highlights
| Old Names | [PureCircle Limited, Pure Global Cannabis Inc, Purefun Group AB] |
| Business Concentration | Jakarta Stock Exchange, Consumer Staples, Household Products, Household & Personal Products, Consumer Defensive (View all Sectors) |
Pure Bioscience [PURE] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pure Bioscience's market, we take the total number of its shares issued and multiply it by Pure Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Pure Bioscience conducts business under Household Products sector and is part of Consumer Staples industry. The entity has 111.36 M outstanding shares of which 222.97 K shares are at this time shorted by private and institutional investors with about 2.56 trading days to cover.
Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Pure Bioscience Probability Of Bankruptcy
Ownership AllocationPure Bioscience owns a total of 111.36 Million outstanding shares. Pure Bioscience has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pure Ownership Details
Pure Bioscience Risk Profiles
| Mean Deviation | 3.56 | |||
| Standard Deviation | 7.91 | |||
| Variance | 62.51 | |||
| Risk Adjusted Performance | (0.03) |
Pure Stock Against Markets
Picking the right benchmark for Pure Bioscience otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Pure Bioscience otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Pure Bioscience is critical whether you are bullish or bearish towards Pure Bioscience at a given time. Please also check how Pure Bioscience's historical prices are related to one of the top price index indicators.
Pure OTC Stock Analysis Notes
About 41.0% of the company outstanding shares are owned by corporate insiders. The book value of Pure Bioscience was at this time reported as 0.03. The company recorded a loss per share of 0.04. Pure Bioscience had not issued any dividends in recent years. The entity had 1:8 split on the 15th of August 2012. PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.The quote for Pure Bioscience is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Pure Bioscience contact Tom CPA at 619 596 8600 or learn more at https://www.purebio.com.Pure Bioscience Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Pure Bioscience's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Pure Bioscience or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Pure Bioscience generated a negative expected return over the last 90 days | |
| Pure Bioscience has high historical volatility and very poor performance | |
| Pure Bioscience has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
Pure Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pure Bioscience's market, we take the total number of its shares issued and multiply it by Pure Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Pure Profitablity
Pure Bioscience's profitability indicators refer to fundamental financial ratios that showcase Pure Bioscience's ability to generate income relative to its revenue or operating costs. If, let's say, Pure Bioscience is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Pure Bioscience's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Pure Bioscience's profitability requires more research than a typical breakdown of Pure Bioscience's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.98) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.98. Technical Drivers
As of the 29th of January, Pure Bioscience holds the Coefficient Of Variation of (1,902), risk adjusted performance of (0.03), and Variance of 62.51. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pure Bioscience, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Pure Bioscience, which can be compared to its competitors. Please check Pure Bioscience risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Pure Bioscience is priced some-what accurately, providing market reflects its current price of 0.0496 per share. As Pure Bioscience appears to be a penny stock we also advise to check out its jensen alpha numbers.Pure Bioscience Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Pure Bioscience Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Pure Bioscience price patterns.
Pure Bioscience Outstanding Bonds
Pure Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pure Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pure bonds can be classified according to their maturity, which is the date when Pure Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Pure Bioscience Predictive Daily Indicators
Pure Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pure Bioscience otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 501.71 | |||
| Daily Balance Of Power | (0.06) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 0.0461 | |||
| Day Typical Price | 0.0473 | |||
| Price Action Indicator | 0.0033 | |||
| Period Momentum Indicator | (0.0004) | |||
| Relative Strength Index | 45.48 |
Pure Bioscience Forecast Models
Pure Bioscience's time-series forecasting models are one of many Pure Bioscience's otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pure Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Pure Bioscience without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Pure Bioscience Corporate Management
Elected by the shareholders, the Pure Bioscience's board of directors comprises two types of representatives: Pure Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pure. The board's role is to monitor Pure Bioscience's management team and ensure that shareholders' interests are well served. Pure Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pure Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Elliott | Principal Financial and Accounting Officer and VP of Fin. | Profile | |
| Tom CPA | Pres CEO | Profile | |
| Thomas Myers | COO Director | Profile | |
| John Kasperski | VP Sales | Profile | |
| Zhinong Yan | Exec Devel | Profile |
Other Information on Investing in Pure OTC Stock
Pure Bioscience financial ratios help investors to determine whether Pure OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pure with respect to the benefits of owning Pure Bioscience security.